CL2021000618A1 - Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo - Google Patents

Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo

Info

Publication number
CL2021000618A1
CL2021000618A1 CL2021000618A CL2021000618A CL2021000618A1 CL 2021000618 A1 CL2021000618 A1 CL 2021000618A1 CL 2021000618 A CL2021000618 A CL 2021000618A CL 2021000618 A CL2021000618 A CL 2021000618A CL 2021000618 A1 CL2021000618 A1 CL 2021000618A1
Authority
CL
Chile
Prior art keywords
same
pharmaceutical composition
oxadiazole
composition containing
compound
Prior art date
Application number
CL2021000618A
Other languages
English (en)
Inventor
Ju Young Lee
Eun Ju Choi
Choon Ho Ryu
Min Soo Han
Yeo Jin Yoon
Yu Jin Kim
Ka Eun Lee
Myung Jin Jung
Eun Hee Baek
Yu Jin Shin
Young Soon Kang
Yong Soo Kim
Yea Mi Song
Jin Sung Kim
Hee Jeong Lim
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of CL2021000618A1 publication Critical patent/CL2021000618A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se describe en la presente invención un compuesto de oxadiazol y sales farmacéuticamente útiles del mismo. El compuesto y sales farmacéuticamente útiles del mismo son especialmente adecuadas para el tratamiento de enfermedades del sistema nervioso tal como epilepsia.
CL2021000618A 2018-09-21 2021-03-12 Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo CL2021000618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180113956 2018-09-21

Publications (1)

Publication Number Publication Date
CL2021000618A1 true CL2021000618A1 (es) 2021-08-06

Family

ID=69887571

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000618A CL2021000618A1 (es) 2018-09-21 2021-03-12 Compuesto que contiene oxadiazol y composición farmacéutica que contiene el mismo

Country Status (16)

Country Link
US (4) US11053208B2 (es)
EP (1) EP3854788A4 (es)
JP (1) JP7430175B2 (es)
KR (1) KR102827846B1 (es)
CN (1) CN113272285B (es)
AR (1) AR118413A1 (es)
AU (1) AU2019341357B2 (es)
BR (1) BR112021005269A2 (es)
CA (1) CA3112700A1 (es)
CL (1) CL2021000618A1 (es)
IL (1) IL281553B2 (es)
MX (1) MX2021003204A (es)
MY (1) MY206736A (es)
TW (1) TWI826531B (es)
WO (1) WO2020060299A1 (es)
ZA (1) ZA202101520B (es)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US21121A (en) 1858-08-10 Appabattjs for purifying gas
IE49823B1 (en) 1979-06-01 1985-12-25 Wellcome Found 1,2,4-triazine derivatives,process for preparing such compounds and pharmaceutical compositions containing them
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
KR0162036B1 (ko) 1996-05-31 1998-12-01 추호석 스택커 크래인의 모터 제어장치 및 방법
JP2003524595A (ja) 1998-07-08 2003-08-19 モナシュ ユニバーシティ 薬 剤
UA78211C2 (en) 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
AU2005271669A1 (en) * 2004-08-03 2006-02-16 Merck & Co., Inc. 1,3-disubstituted heteroaryl NMDA/NR2B antagonists
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EP2051964A4 (en) * 2006-07-28 2012-03-07 Univ Connecticut INHIBITORS OF FATTY ACID AMIDHYDROLASE
CN102015637B (zh) 2008-02-06 2014-05-21 第一三共株式会社 苯基吡咯衍生物
CA2785679C (en) 2009-12-28 2017-12-12 General Incorporated Association Pharma Valley Project Supporting Organization 1,3,4-oxadiazole-2-carboxamide compound
EP2544679B1 (en) * 2010-03-12 2019-05-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
WO2017060488A1 (en) * 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists

Also Published As

Publication number Publication date
KR20210047889A (ko) 2021-04-30
JP2022503775A (ja) 2022-01-12
US20220024886A1 (en) 2022-01-27
US11053208B2 (en) 2021-07-06
US12145914B2 (en) 2024-11-19
AU2019341357B2 (en) 2023-03-02
EP3854788A1 (en) 2021-07-28
MX2021003204A (es) 2021-05-27
TW202023547A (zh) 2020-07-01
AR118413A1 (es) 2021-10-06
TWI826531B (zh) 2023-12-21
JP7430175B2 (ja) 2024-02-09
BR112021005269A2 (pt) 2021-06-15
CA3112700A1 (en) 2020-03-26
US20230150955A1 (en) 2023-05-18
MY206736A (en) 2025-01-03
US20210115001A1 (en) 2021-04-22
US20250034101A1 (en) 2025-01-30
KR102827846B1 (ko) 2025-07-01
WO2020060299A1 (ko) 2020-03-26
CN113272285A (zh) 2021-08-17
CN113272285B (zh) 2024-06-07
ZA202101520B (en) 2022-08-31
US11603358B2 (en) 2023-03-14
AU2019341357A1 (en) 2021-04-08
IL281553A (en) 2021-05-31
IL281553B1 (en) 2025-02-01
IL281553B2 (en) 2025-06-01
EP3854788A4 (en) 2022-06-15

Similar Documents

Publication Publication Date Title
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2017015470A (es) Inhibidores de tirosina-cinasas.
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
ECSP17002135A (es) Compuestos antiproliferativos y métodos de uso de los mismos
UY37205A (es) Inhibidores de bromodominios
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
MX2022005256A (es) Inhibidores de cd73.
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
UY36003A (es) Derivados de amida, procesos de preparación y composiciones, útiles en afecciones asociadas con el receptor sub-tipo 1 de orexina.
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
CL2021001244A1 (es) Compuestos antibióticos, métodos de fabricación de los mismos, composiciones farmacéuticas conteniendo los mismos y usos de los mismos
CL2019002583A1 (es) Inhibidores duales de magl y faah.
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
MX2017012238A (es) Inhibidores de la polimerasa del virus de la hepatitis c.
CO2018002428A2 (es) Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol
ECSP21062210A (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
MX374705B (es) Composiciones que comprenden anakinra.
CL2017002229A1 (es) Inhibidores de bace1.
MX2018005100A (es) Compuestos de dibenzo-azepina y su uso en el tratamiento de enfermedades y trastornos oticos.